<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176005</url>
  </required_header>
  <id_info>
    <org_study_id>DAV132-CL-1002</org_study_id>
    <secondary_id>ID-RCB number 2013-A01504-41</secondary_id>
    <nct_id>NCT02176005</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of DAV132 in Healthy Volunteers</brief_title>
  <official_title>Influence of the Administration of DAV132 7.5g Tid for 7 Days on the Fecal Levels of Moxifloxacin During and After a 5-day Oral Treatment With Moxifloxacin 400mg Oad in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Da Volterra</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Da Volterra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DAV132 is safe and effective for capturing
      fecal residues of moxifloxacin in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study, DAV132-CL-1002, is to evaluate performances of DAV132 in healthy
      volunteers:

        -  To capture residual concentration of antibiotics in colon without interfering with their
           systemic pharmacokinetics parameters.

        -  To explore the influence of DAV132 to prevent the modification of gut flora due to
           antibiotic.

      In addition, the security and acceptability of DAV132 used during 7 days will be evaluated.

      The proposed study is prospective, randomized, controlled, four parallel groups, repeated
      doses, open-label study blinded to analytical and microbiological evaluations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 16 Days After the Beginning of Treatment (AUC D1-D16)</measure>
    <time_frame>D1 pre-dose, D2, D3, D4, D5, D6, D7, D8, D9, D12, D16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 37 Days After the Beginning of Treatment (AUC D1-D37)</measure>
    <time_frame>D1 pre-dose, D2, D3, D4, D5, D6, D7, D8, D9, D12, D16, D23, D30, D37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D1</measure>
    <time_frame>D1: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h and 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D5</measure>
    <time_frame>D5: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h; 24h; 32h; 48h; 56h and 72h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D1</measure>
    <time_frame>D1: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h and 24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D5</measure>
    <time_frame>D5: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h; 24h; 32h; 48h; 56h and 72h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (Including Abnormal Laboratory Findings) Related to Study Product</measure>
    <time_frame>From randomization to 37 days after the beginning of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Adverse Events Related to Study Product</measure>
    <time_frame>From randomization to 37 days after the beginning of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin, oral tablets, 400mg/day, once daily 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>moxifloxacin + DAV132</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAV132</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DAV132 oral, 7.5g x3/day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Negative control: 7.5g x3/day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DAV132</intervention_name>
    <description>DAV132 is associated to moxifloxacin or it is evaluated alone</description>
    <arm_group_label>DAV132</arm_group_label>
    <arm_group_label>moxifloxacin + DAV132</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin is used alone or associated to DAV132</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_label>moxifloxacin + DAV132</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Negative Control</intervention_name>
    <description>Moxifloxacin is used alone</description>
    <arm_group_label>Negative control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Normal digestive transit, with usually one daily stool.

          -  Females participating in the study :

        must be either of non-child bearing potential (surgically sterilized at least 3 months
        prior to inclusion, or postmenopausal or having a negative pregnancy test and be not
        breastfeeding at screening, and using abstinence or a double contraception method during
        the treatment period and for additional period of 2 weeks after the end of investigational
        treatment.

          -  Having given and signed the written study informed consent prior to undertaking any
             study-related procedure.

          -  Covered by the French Health Insurance system.

        Exclusion Criteria:

          -  Any history or presence of clinically relevant cardiovascular, pulmonary,
             gastrointestinal, hepatic, renal, metabolic, haematological, neurological, bone and
             joint, muscular, psychiatric, systemic, ocular, gynaecologic (if female), or
             infectious disease, or signs of acute illness.

          -  Contra-indications to fluoroquinolones, or risk factors for adverse events associated
             to fluoroquinolones.

          -  Subjects with a family history of, or actual glucose-6-phosphate dehydrogenase
             deficiency should be excluded.

          -  Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase
             deficiency or glucose-galactose malabsorption should be excluded.

          -  Contra-indications to DAV132, risk of gastrointestinal obstruction, perforation or
             haemorrhage, recent digestive tract surgery.

          -  Fecal colonisation by Clostridium difficile.

          -  Recent history of hospitalisation (within 3 months prior to inclusion).

          -  Any antibiotic administration within 3 months before inclusion.

          -  Any vaccination within the last 28 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Duval, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC Bichat, Paris France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CLINICAL INVESTIGATION CENTER (CIC), Groupe Hospitalier Bichat-Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75O18</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Edlund C, Beyer G, Hiemer-Bau M, Ziege S, Lode H, Nord CE. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis. 2000;32(1):81-5.</citation>
    <PMID>10716083</PMID>
  </reference>
  <reference>
    <citation>Burkhardt O, Borner K, Stass H, Beyer G, Allewelt M, Nord CE, Lode H. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand J Infect Dis. 2002;34(12):898-903.</citation>
    <PMID>12587622</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <results_first_submitted>July 5, 2019</results_first_submitted>
  <results_first_submitted_qc>February 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2020</results_first_posted>
  <last_update_submitted>February 16, 2020</last_update_submitted>
  <last_update_submitted_qc>February 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy volunteers were recruited from March 20th, 2014 (date of first enrolment) and October 17th, 2014 (date of last completed)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Moxifloxacin</title>
          <description>Moxifloxacin (oral tablets, 400mg x1/day for 5 days) used alone</description>
        </group>
        <group group_id="P2">
          <title>DAV132 + Moxifloxacin</title>
          <description>DAV132 (7.5g x3/day taken orally for 7 days) associated to Moxifloxacin (400mg x1/day taken orally for 5 days)</description>
        </group>
        <group group_id="P3">
          <title>DAV132</title>
          <description>DAV132 (7.5g x3/day taken orally for 7 days) used alone</description>
        </group>
        <group group_id="P4">
          <title>Negative Control</title>
          <description>Negative control: microcrystalline cellulose (7.5g x3/day taken orally for 7 days)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Moxifloxacin</title>
          <description>Moxifloxacin (400mg x1/day taken orally for 5 days) used alone</description>
        </group>
        <group group_id="B2">
          <title>DAV132 + Moxifloxacin</title>
          <description>DAV132 (7.5g x3/day taken orally for 7 days) associated to Moxifloxacin (400mg x1/day taken orally for 5 days)</description>
        </group>
        <group group_id="B3">
          <title>DAV132</title>
          <description>DAV132 (7.5g x3/day taken orally for 7 days) used alone</description>
        </group>
        <group group_id="B4">
          <title>Negative Control</title>
          <description>Negative control: microcrystalline cellulose (7.5g x3/day taken orally for 7 days)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.4" spread="10.4"/>
                    <measurement group_id="B2" value="38.6" spread="12.1"/>
                    <measurement group_id="B3" value="27.9" spread="9.1"/>
                    <measurement group_id="B4" value="36.7" spread="11.8"/>
                    <measurement group_id="B5" value="35.3" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) at screening visit</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.1" spread="3.3"/>
                    <measurement group_id="B2" value="24.9" spread="3.2"/>
                    <measurement group_id="B3" value="23.6" spread="3.2"/>
                    <measurement group_id="B4" value="23.3" spread="2.0"/>
                    <measurement group_id="B5" value="24.1" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 16 Days After the Beginning of Treatment (AUC D1-D16)</title>
        <time_frame>D1 pre-dose, D2, D3, D4, D5, D6, D7, D8, D9, D12, D16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin + DAV132</title>
            <description>Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
DAV132: DAV132 is associated to moxifloxacin or it is evaluated alone
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
        </group_list>
        <measure>
          <title>Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 16 Days After the Beginning of Treatment (AUC D1-D16)</title>
          <units>μg/g.day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="758.4" spread="359.3"/>
                    <measurement group_id="O2" value="8.28" spread="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.000001</p_value>
            <method>General linear model</method>
            <param_type>Contrast (B/A)</param_type>
            <param_value>0.0093</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0060</ci_lower_limit>
            <ci_upper_limit>0.0144</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 37 Days After the Beginning of Treatment (AUC D1-D37)</title>
        <time_frame>D1 pre-dose, D2, D3, D4, D5, D6, D7, D8, D9, D12, D16, D23, D30, D37</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin + DAV132</title>
            <description>Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
DAV132: DAV132 is associated to moxifloxacin or it is evaluated alone
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
        </group_list>
        <measure>
          <title>Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 37 Days After the Beginning of Treatment (AUC D1-D37)</title>
          <units>μg/g.day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="758.7" spread="359.5"/>
                    <measurement group_id="O2" value="8.74" spread="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.000001</p_value>
            <method>General linear model</method>
            <param_type>Contrast (B/A)</param_type>
            <param_value>0.0096</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0061</ci_lower_limit>
            <ci_upper_limit>0.0151</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D1</title>
        <time_frame>D1: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h and 24h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin + DAV132</title>
            <description>Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
DAV132: DAV132 is associated to moxifloxacin or it is evaluated alone
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
        </group_list>
        <measure>
          <title>Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D1</title>
          <units>µg/mL.h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" spread="7.01"/>
                    <measurement group_id="O2" value="41.9" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.806</p_value>
            <method>General linear model</method>
            <param_type>Contrast (B/A)</param_type>
            <param_value>0.9811</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8608</ci_lower_limit>
            <ci_upper_limit>1.1182</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D5</title>
        <time_frame>D5: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h; 24h; 32h; 48h; 56h and 72h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin + DAV132</title>
            <description>Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
DAV132: DAV132 is associated to moxifloxacin or it is evaluated alone
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
        </group_list>
        <measure>
          <title>Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D5</title>
          <units>µg/mL.h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6" spread="13.83"/>
                    <measurement group_id="O2" value="50.5" spread="10.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.139</p_value>
            <method>General linear model</method>
            <param_type>Contrast (B/A)</param_type>
            <param_value>0.8785</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7600</ci_lower_limit>
            <ci_upper_limit>1.0155</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D1</title>
        <time_frame>D1: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h and 24h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin + DAV132</title>
            <description>Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
DAV132: DAV132 is associated to moxifloxacin or it is evaluated alone
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
        </group_list>
        <measure>
          <title>Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D1</title>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="1.33"/>
                    <measurement group_id="O2" value="4.63" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.104</p_value>
            <method>General linear model</method>
            <param_type>Contrast (B/A)</param_type>
            <param_value>1.1763</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9982</ci_lower_limit>
            <ci_upper_limit>1.3861</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D5</title>
        <time_frame>D5: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h; 24h; 32h; 48h; 56h and 72h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin + DAV132</title>
            <description>Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
DAV132: DAV132 is associated to moxifloxacin or it is evaluated alone
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
        </group_list>
        <measure>
          <title>Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D5</title>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.89" spread="1.21"/>
                    <measurement group_id="O2" value="4.60" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.519</p_value>
            <method>General linear model</method>
            <param_type>Contrast (B/A)</param_type>
            <param_value>0.9391</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7969</ci_lower_limit>
            <ci_upper_limit>1.1066</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (Including Abnormal Laboratory Findings) Related to Study Product</title>
        <time_frame>From randomization to 37 days after the beginning of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin + DAV132</title>
            <description>Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
DAV132: DAV132 is associated to moxifloxacin or it is evaluated alone
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
          <group group_id="O3">
            <title>DAV132</title>
            <description>DAV132 oral, 7.5g x3/day for 7 days
DAV132: DAV132 is associated to moxifloxacin or it is evaluated alone</description>
          </group>
          <group group_id="O4">
            <title>Negative Control</title>
            <description>Negative control: 7.5g x3/day for 7 days
Negative Control: Moxifloxacin is used alone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (Including Abnormal Laboratory Findings) Related to Study Product</title>
          <units>events related to study product</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Adverse Events Related to Study Product</title>
        <time_frame>From randomization to 37 days after the beginning of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
          <group group_id="O2">
            <title>Moxifloxacin + DAV132</title>
            <description>Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
DAV132: DAV132 is associated to moxifloxacin or it is evaluated alone
Moxifloxacin: Moxifloxacin is used alone or associated to DAV132</description>
          </group>
          <group group_id="O3">
            <title>DAV132</title>
            <description>DAV132 oral, 7.5g x3/day for 7 days
DAV132: DAV132 is associated to moxifloxacin or it is evaluated alone</description>
          </group>
          <group group_id="O4">
            <title>Negative Control</title>
            <description>Negative control: 7.5g x3/day for 7 days
Negative Control: Moxifloxacin is used alone</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Adverse Events Related to Study Product</title>
          <units>% of subjects with at last 1 related AE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.14"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment period: - 5 days for Moxifloxacin group; - 7 days for the 3 other groups (DAV132 + Moxifloxacin, DAV132 and Negative Control groups)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Moxifloxacin</title>
          <description>Moxifloxacin (400mg x1/day taken orally for 5 days) used alone</description>
        </group>
        <group group_id="E2">
          <title>Moxifloxacin + DAV132</title>
          <description>DAV132 (7.5g x3/day taken orally for 7 days) associated to Moxifloxacin (400mg x1/day taken orally for 5 days)</description>
        </group>
        <group group_id="E3">
          <title>DAV132</title>
          <description>DAV132 (7.5g x3/day taken orally for 7 days) used alone</description>
        </group>
        <group group_id="E4">
          <title>Negative Control</title>
          <description>Negative control: microcrystalline cellulose (7.5g x3/day taken orally for 7 days)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intestinal transit time abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Formication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Annie Ducher, Chief Medical Officer</name_or_title>
      <organization>Da Volterra</organization>
      <phone>+33 1 58 39 32 20</phone>
      <email>annie.ducher@davolterra.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

